Ace Vision Group Names Ken Araki to Its Board of Directors
Ace Vision Group, Inc., an emerging medical device company at the forefront of pioneering rejuvenation therapy for the aging eye, today announced that it has named Ken Araki to its board of directors. Mr. Araki brings executive management experience and strategic leadership skills to support and drive commercial planning for the VisioLite® laser. The laser restores the eye’s natural dynamic range of focus through Laser Scleral Microporation (LSM), allowing patients to see clearly at all distances with the eye’s natural functionality. The VisioLite® Ophthalmic Laser System & LSM are not yet FDA approved or available in the United States. It is currently in clinical trials only in select areas outside of the United States.
Explore More Articles
Microporation may address aging in eye
LAS VEGAS — In this Healio Video Perspective from the ASCRS meeting, AnnMarie Hipsley, DPT, PhD, discusses microporation therapeutics and its potential role in presbyopia treatment.
read moreInfluence of Ocular Rigidity and Ocular Biomechanics on the Pathogenesis of Age-Related Presbyopia
This chapter discusses ocular rigidity and ocular biomechanical dysfunction as they relate to the age-related pathogenesis of presbyopia. The major factors associated with presbyopia as they relate to ocular rigidity and ocular biomechanical dysfunction are highlighted. Furthermore, specific reference is made to modifying the biomechanical properties and structural stiffness of the scleral outer coat utilizing …
read moreAce Vision Group Names Ken Araki to Its Board of Directors
Ace Vision Group, Inc., an emerging medical device company at the forefront of pioneering rejuvenation therapy for the aging eye, today announced that it has named Ken Araki to its board of directors. Mr. Araki brings executive management experience and strategic leadership skills to support and drive commercial planning for the VisioLite® laser. The laser …
read more